BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8004757)

  • 1. In vivo modulation of several anticancer agents by beta-carotene.
    Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
    Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
    Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
    Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-carotene and/or vitamin E as modulators of alkylating agents in SCC-25 human squamous carcinoma cells.
    Schwartz JL; Tanaka J; Khandekar V; Herman TS; Teicher BA
    Cancer Chemother Pharmacol; 1992; 29(3):207-13. PubMed ID: 1733553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
    Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
    Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
    Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
    Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
    Teicher BA; Holden SA; Liu CJ; Ara G; Herman TS
    Cancer Lett; 1994 Jul; 82(1):17-25. PubMed ID: 8033065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase inhibitors - invitro and invivo effects on antitumor alkylating-agents in the emt-6 murine mammary-carcinoma.
    Teicher B; Holden S; Ara G; Liu J; Robinson M; Flodgren P; Dupuis N; Northey D
    Int J Oncol; 1993 Feb; 2(2):145-53. PubMed ID: 21573528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L; Korbut T; Herman TS; Teicher BA
    Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
    Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
    Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
    Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
    Teicher BA; Liu SD; Liu JT; Holden SA; Herman TS
    Anticancer Res; 1993; 13(5A):1549-56. PubMed ID: 8239534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preclinical model for sequential high-dose chemotherapy.
    Holden SA; Teicher BA; Ayash LJ; Frei E
    Cancer Chemother Pharmacol; 1995; 36(1):61-4. PubMed ID: 7720177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.